ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Optimal early treatment of ST-segment elevation myocardial infarction (STEMI) requires effective antiplatelet therapy to prevent recurrent myocardial infarction and restenosis.
• Acetylsalicylic acid (ASA; aspirin) is a traditional antiplatelet but targets only one pathway of platelet aggregation.
• Glycoprotein IIb/IIIa inhibitors are generally contraindicated with fibrinolytic agents in acute STEMI due to increased intracranial hemorrhage risk.

Purpose of the Study:

• To evaluate the efficacy and safety of aggressive antiplatelet therapy in STEMI patients undergoing primary percutaneous coronary intervention.
• To explore the synergistic potential of combining antiplatelet agents with different mechanisms of action.

Main Methods:

• Review of recent clinical trials investigating antiplatelet strategies in STEMI.
• Comparison of outcomes (mortality, restenosis, bleeding) associated with different antiplatelet regimens.

Main Results:

• Aggressive antiplatelet therapy with clopidogrel, in combination with aspirin, significantly reduces mortality in STEMI patients.
• This combination therapy offers substantial clinical benefits without a corresponding increase in major bleeding events.
• Synergistic effects of combining antiplatelet agents with distinct inhibitory mechanisms are supported by recent evidence.

Conclusions:

• An early and aggressive antiplatelet strategy using aspirin and clopidogrel is recommended for STEMI patients.
• This approach achieves more complete platelet inhibition, optimizing outcomes after primary percutaneous coronary intervention.
• The combination of aspirin and clopidogrel represents a safe and effective strategy for managing STEMI.